Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $22.9B | $22.0B | $22.6B | $24.2B | $23.9B | $27.4B | $46.0B | $48.0B | $47.3B | $44.0B | $42.2B | $39.5B | $39.8B | $40.1B | $42.3B | $46.8B | $41.5B | $48.7B | $59.3B | $60.1B |
Discover the top 20 best undervalued stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Nov 2024.
As of today, Merck & Co., Inc.'s last 12-month Revenue is $63.2B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Merck & Co., Inc.'s Revenue growth was 6.6%. The average annual Revenue growth rates for Merck & Co., Inc. have been 13.3% over the past three years, 6.6% over the past five years.
Over the last year, Merck & Co., Inc.'s Revenue growth was 6.6%, which is higher than industry growth of 0.1%. It indicates that Merck & Co., Inc.'s Revenue growth is Good.